This second course in the Biosimilars Continuing Education Series entitled "Biosimilars - Substitution and Interchangeability" will examine U.S. biosimilar substitution policy and practices and will compare these with those of other countries. Physician and patient concerns with these practices will also be discussed. This is the second of seven courses in the Biosimilars Continuing Education Series. Your course facilitator for "Biosimilars - Substitution and Interchangeability" is Professor Phil Schneider.

After completing this module, the participant should be able to:

1. Discuss patient and physician concerns with third-party substitution of biosimilars.
2. Explain the concept of interchangeability- how it addresses physician and patient concerns; and what it means for pharmacy-level substitution of biologics.
3. Discuss the current status of US biosimilar substitution policy and its evolution at the state level.
4. Compare the US approach to automatic substitution with those of other countries including Australia, Canada, and those in Western and Eastern Europe.

The College of Pharmacy at The Ohio State University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal program number 0633-0000-22-020-H01-P. Participants must view the video, achieve an 80% on the quiz and complete the evaluation to receive CE credit for program. Questions about pharmacist's participation in the program and continuing education credit should be addressed to Brooke Keber at cop-cpd@osu.edu.